Making it in Manufacturing

This week on Making It In Manufacturing, Elliot Payne sat down again with Himanshu Gadgil, Ph.D., CEO of Enzene, at CPHI Milan 2026, where ARTO was the official podcast partner.In this episode, Himanshu covers:(00:54) Enzene's last 12 months: the Manufacturing Excellence Award, its New Jersey facility fully running with two suites, and a full technology transfer offer for anyone who wants to onshore manufacturing.(02:12) Why Enzene is opening up its continuous manufacturing platform: to reach the tipping point where a lot more people adopt it.(02:59) The biosimilar boom seen at CPHI this year, and why the supply and demand equation has flipped.(04:30) How Enzene stands out: a platform built for India's price-sensitive market, so it was cost effective from the start.(05:58) What comes next for EnzeneX®: from 200 litres to 1,000 litres in 2.0, then process analytics, its own media, and AI that makes process decisions dynamically.(07:23) Intuition or data: how he makes decisions, and how AI gives the team very quick access to what the data is saying.(08:59) The decisions that shaped Enzene: becoming a full CDMO, and moving into pet health, where it works with four of the top five pet health companies.(10:13) The one process he would remove from pharma manufacturing.Watch the full episode to hear why Himanshu believes the best cost of goods will win as so many biologics come off patent.Register your interest for CPHI Frankfurt 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-artoFollow ARTOLinkedIn: https://www.linkedin.com/company/artotalent/Spotify: https://open.spotify.com/show/1cSZVJ63yXJ3kqnVORyTbwInstagram: https://www.instagram.com/arto.talentTikTok: https://www.tiktok.com/@artotalentApple Podcasts: https://podcasts.apple.com/gb/podcast/making-it-in-manufacturing/id1819731245Website: https://arto-talent.com/Youtube: https://www.youtube.com/@artotalentHimanshu GadgilLinkedIn: https://www.linkedin.com/in/himanshu-gadgil-3326307/Elliot PayneLinkedIn: https://www.linkedin.com/in/elliot-payne-2a4a917a/Timestamps:00:00 Introduction00:54 Enzene's last 12 months02:12 Opening up continuous manufacturing02:59 The biosimilar boom04:30 Winning on cost of goods05:58 EnzeneX® 3.0 and beyond07:23 Intuition, data and AI08:59 Decisions that shaped Enzene10:13 One thing to remove from the industry#MakingItInManufacturing #ARTOTalent #CPHI #CPHIMilan #Biosimilars #ContinuousManufacturing #Biologics #CDMO Hosted on Acast. See acast.com/privacy for more information.

Register your interest for 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-artoMany in the pharma industry know CurTec for its white drums with the red lid, used to handle, store and contain the ingredients that go into medicines. CEO Bart van Berkel explains why pharma is the only industry CurTec focuses on.This week on Making It In Manufacturing, Harry Sloan sat down with Bart van Berkel, CEO of CurTec, at CPHI Milan 2026, where ARTO was the official podcast partner.In this episode, Bart covers:(01:00) What CurTec does: packaging that helps pharmaceutical companies, API and excipient suppliers and CMOs handle, store and contain the ingredients used to make medicines.(01:32) What carried over from aerospace: a highly regulated industry, long customer relationships, high standards of quality, and approval processes that take long for a good reason.(02:59) What makes a drum or pail pharmaceutical grade: easy to operate in suits and gloves, screw lids, GMP at the core, and designs that can dock to isolators.(04:16) Sustainability: taking material out, packaging that can be reused, and a redesigned drum with no handles or rubber gasket and a 30% CO2 reduction against CurTec's own products.(05:27) Why CurTec, opened in the 1950s in the Netherlands, built a factory in South Carolina and moved all its American customers to it.(07:35) Building greenfield to embed the CurTec culture of safety, compliance and cleanliness from the start, with a team of 30 and growing.(08:52) How pharma supply chains are shifting, and CurTec's commercial team in Asia working with suppliers of APIs and excipients.(10:01) Where CurTec could be in five years: very likely a facility in Asia, and new products that take it closer to pharma operations.(10:49) What he wants people to remember: CurTec is super dedicated to the pharma industry.Watch the full episode to hear why Bart wants anyone with a packaging problem to give CurTec a call.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalent/Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ngInstagram: https://www.instagram.com/arto.talentTikTok: https://www.tiktok.com/@artotalentApple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575Website: https://arto-talent.com/Youtube: https://www.youtube.com/@artotalentBart van BerkelLinkedIn: https://www.linkedin.com/in/bart-van-berkel-3824b3/Harry SloanLinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/Timestamps:00:00 Introduction01:00 What CurTec does01:32 From aerospace to pharma02:59 What makes packaging pharma grade04:16 Sustainability and lighter drums05:27 Why South Carolina07:35 Building the CurTec culture08:52 How pharma supply chains are changing10:01 CurTec in five years10:49 What to remember about CurTec#MakingItInManufacturing #ARTOTalent #CPHI #CPHIMilan #PharmaPackaging #Sustainability #GMP #PharmaSupplyChain Hosted on Acast. See acast.com/privacy for more information.

Register your interest for 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-artoOn the first day of CPHI Milan 2026, the Digital CMC Consortium launched: a pre-competitive, not-for-profit collaboration across the industry to digitise end-to-end CMC, founded with participation from companies including Novartis, Takeda and Thermo Fisher.On Newsbeat, live at CPHI Milan 2026, Ruby Collier spoke to Luke Guerrero, one of the founding members and now Director of Operations of the Digital CMC Consortium, about the launch and what comes next.In this episode, Luke covers:(00:26) The launch: why biotechs, sponsors, CDMOs and consultancies have come together to solve the problems that can only be solved together.(01:18) Why sponsor to CDMO technology transfer is the first use case, and what a frictionless transfer would look like: as easy as moving to a new phone, instead of typing in every contact by hand.(02:55) How the consortium will turn standards into day-to-day practice: starting from the real workflow between sponsor and CDMO, building in pieces and iterating with members, and working with existing standards rather than replacing them.(04:27) What the consortium wants from the CPHI community: the varied perspectives of sponsors, CDMOs and equipment makers across the whole CMC value chain.Watch the full episode to hear how the Digital CMC Consortium plans to make tech transfer easier, so teams can focus on the real science.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalent/Spotify: https://open.spotify.com/show/1cSZVJ63yXJ3kqnVORyTbwInstagram: https://www.instagram.com/arto.talentTikTok: https://www.tiktok.com/@artotalentApple Podcasts: https://podcasts.apple.com/gb/podcast/making-it-in-manufacturing/id1819731245Website: https://arto-talent.com/Youtube: https://www.youtube.com/@artotalentLuke GuerreroLinkedIn: https://www.linkedin.com/in/lukeguerrero/Ruby CollierLinkedIn: https://www.linkedin.com/in/ruby-collier/Timestamps:00:00 Introduction00:22 The launch of the Digital CMC Consortium01:06 Why tech transfer is the first use case02:46 Turning shared standards into everyday practice04:18 What the consortium wants from the CPHI community05:05 Closing thoughts#Newsbeat #ARTOTalent #CPHI #CPHIMilan #CMC #TechTransfer #DigitalTransformation #CDMO #Pharma Hosted on Acast. See acast.com/privacy for more information.

Register your interest for 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-artoQuotient Sciences has announced interim results from its AI-driven clinical trial. After three years developing AI for formulation development, with 30 to 50% time savings, Quotient took the approach into the clinic to see if it could also learn how a formulation's composition relates to its performance in people.On Newsbeat, live at CPHI Milan 2026, Ruby Collier spoke to Andy Lewis, Chief Scientific Officer of Quotient Sciences, about the results and what they could mean for drug development.In this episode, Andy covers:(00:25) The interim results: the AI appears to have learned the link between composition and in vivo performance after testing just three prototypes, which could reduce the clinical testing a product needs.(01:25) How the algorithm learned: active learning with Bayesian optimisation, starting untrained, trained first on in vitro data and then on the emerging clinical data, with a safety committee reviewing every formulation it requested. When the team changed the target to rule out luck, it hit that one too.(03:27) What it could mean for modified release products: fewer formulation screens, faster clinical development, and an in silico model of the drug product, like a digital twin, that could support scale-up and post-approval changes such as a change of site.(05:05) What drug developers at CPHI Milan are most excited about: a first look at the pharmacokinetic data, and how the tool's visualisations map onto quality by design.Watch the full episode to hear how Quotient Sciences is using AI to save time at every step of drug product development.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalent/Spotify: https://open.spotify.com/show/1cSZVJ63yXJ3kqnVORyTbwInstagram: https://www.instagram.com/arto.talentTikTok: https://www.tiktok.com/@artotalentApple Podcasts: https://podcasts.apple.com/gb/podcast/making-it-in-manufacturing/id1819731245Website: https://arto-talent.com/Youtube: https://www.youtube.com/@artotalentAndy LewisLinkedIn: https://www.linkedin.com/in/andylewis1/Ruby CollierLinkedIn: https://www.linkedin.com/in/ruby-collier/Timestamps:00:00 Introduction00:16 Quotient's interim clinical trial results01:25 How the algorithm learned from each dosing period03:27 What it could mean for modified release development05:05 What drug developers at CPHI are excited about06:08 Closing thoughts#Newsbeat #ARTOTalent #CPHI #CPHIMilan #AI #MachineLearning #FormulationDevelopment #DrugDevelopment #ClinicalTrials Hosted on Acast. See acast.com/privacy for more information.

95% of our viewers aren't subscribed. If you're watching and not yet subscribed, please subscribe to the channel so you don't miss future episodes.Register your interest for 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-artoA year ago, InstaPill was adding a new block to take its capacity in India to 500 million units. Now CEO Ankit Gupta plans a new greenfield site to double that to a billion, able to handle everything that is ODT.This week on Making It In Manufacturing, Harry Sloan caught up again with Ankit Gupta, CEO of InstaPill, at CPHI Milan 2026, where ARTO was the official podcast partner.In this episode, Ankit covers:(01:12) Why InstaPill is planning a new greenfield site in India, on about 18 acres of land, modular so capacity can grow with demand.(02:35) The move to a CDMO and B2B model, built on its two strengths: development and manufacturing.(03:55) What sets InstaPill apart: transparency and flexibility, with projects partners typically do in 9 to 10 months delivered in 3 to 6.(05:01) Where a US site fits: the bulk of its partners are in the US, and the plan stays on track for when partners need it.(06:22) What to ask him about next year: more visible partnerships and more products reaching the market.Watch the full episode to hear why Ankit wants partners to think of InstaPill as the company that can do everything that is possible on ODT.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalent/Spotify: https://open.spotify.com/show/1cSZVJ63yXJ3kqnVORyTbwInstagram: https://www.instagram.com/arto.talentTikTok: https://www.tiktok.com/@artotalentApple Podcasts: https://podcasts.apple.com/gb/podcast/making-it-in-manufacturing/id1819731245Website: https://arto-talent.com/Youtube: https://www.youtube.com/@artotalentAnkit GuptaLinkedIn: https://www.linkedin.com/in/reachankit/Harry SloanLinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/Timestamps:00:00 Introduction01:12 Doubling to a billion units02:35 From own products to CDMO partner03:55 Transparency and flexibility05:01 The plan for the US06:22 What to watch for next year#MakingItInManufacturing #ARTOTalent #CPHI #CPHIMilan #ODT #CDMO #DrugDelivery #PharmaManufacturing Hosted on Acast. See acast.com/privacy for more information.

Drug discovery and clinical development have all benefited from the COVID era and the AI era, but for Sheena Dempsey, manufacturing is still stuck somewhat in the dark ages. As President and CEO of CAI, she wants to drive automation and acceleration that get medicines into the hands of patients faster.This week on Making It In Manufacturing, Elliot Payne sat down with Sheena Dempsey, President and CEO of CAI, the global consultancy for commissioning and qualification and operational readiness, at CPHI Milan 2026, where ARTO was the official podcast partner.In this episode, Sheena covers:(00:57) What CAI does: commissioning and qualification, operational readiness and operational excellence for most of the top pharmaceutical companies, with about 750 people across North America, Europe and APAC.(02:06) The new partnership with JLL Partners, and her three to five year plan to grow CAI, organically and inorganically, in footprint and in services.(03:13) What drew her to CAI after building life sciences practices in professional services, and why she calls herself a global misfit.(04:44) Getting experienced people and Gen Z and Gen Alpha digital natives working well together: the goals are the same, and it takes leadership, change management and training on both sides.(06:58) Why paper in manufacturing plants is unacceptable today, and why digitisation lends itself to compliance and stops knowledge being lost.(07:43) What CAI looks for in new people, and managing talent as a portfolio, from trade schools and internships to graduates.(10:03) Why CAI is building its own trade school pipeline for aseptic manufacturing, where the demand for talent is enormous.(12:06) What success in 2027 looks like: the right balance of skills, global teams built around a customer's need, and the excitement of a plant's first batch.(13:31) The one thing she would remove from pharma manufacturing: its deeply held resistance to change.(14:23) Why she is optimistic: pockets of real innovation at particular sites, led by site heads and change agents.Watch the full episode to hear why Sheena believes the inflection point manufacturing needs is already in play.Register your interest for CPHI Frankfurt 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-artoFollow ARTOLinkedIn: https://www.linkedin.com/company/artotalent/Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ngInstagram: https://www.instagram.com/arto.talentTikTok: https://www.tiktok.com/@artotalentApple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575Website: https://arto-talent.com/Youtube: https://www.youtube.com/@artotalentSheena DempseyLinkedIn: https://www.linkedin.com/in/sheena-dempsey-b693575/Elliot PayneLinkedIn: https://www.linkedin.com/in/elliot-payne-2a4a917a/Timestamps:00:00 Introduction00:57 What CAI does02:06 The JLL Partners partnership03:13 Why Sheena chose CAI04:44 Bringing generations together06:58 Taking paper out of manufacturing07:43 What CAI looks for in talent10:03 Building a trade school pipeline12:06 What success looks like in 202713:31 One thing to remove from the industry14:23 Reasons for optimism#MakingItInManufacturing #ARTOTalent #CPHI #CPHIMilan #Commissioning #Qualification #Digitalisation #PharmaManufacturing Hosted on Acast. See acast.com/privacy for more information.

This week on Making It In Manufacturing, we’re bringing you our CEO panel from CPHI Milan 2026. ARTO Co-Founder and CEO Elliot Payne sat down with three CDMO CEOs: Dr Hanns-Christian Mahler of ten23 health, Dr Adriana Kiędzierska-Mencfeld of Rezon Bio and Philippe Clavel of Curapath, to ask how they weigh capacity risk against indication risk. In this panel: - Why ordering a sterile filling machine today can mean five to seven years before the first GMP fill - How Rezon Bio builds capacity in stages, and why the team is the biggest asset and the biggest risk - How Curapath helped an ALS customer go from 16 polymer drug conjugates to four on the way to phase two - Fixed platforms with flexible indications, and when one facility can serve many - The latest build, buy or partner calls each CEO has made - Data or instinct: how they decide where to invest next - The one thing each of them would remove from pharma manufacturingBe sure to watch to the end for the quickfire round. Register your interest for CPHI Frankfurt 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-arto 🤝 Thank you to CPHI and Informa Markets for having us as official podcast partners at CPHI Milan 2026. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent TikTok: https://www.tiktok.com/@artotalent Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ YouTube: https://www.youtube.com/@artotalent Making It In Manufacturing playlist: https://www.youtube.com/playlist?list=PL_xXnfiK8dI5gHJr13c23WSFNHYc4d6_4 The panel :Hanns-Christian Mahler, CEO, ten23 health: https://www.linkedin.com/in/hanns-christian-mahler/ Adriana Kiędzierska-Mencfeld, CEO, Rezon Bio: https://www.linkedin.com/in/dr-adriana-kiedzierska-mencfeld/ Philippe Clavel, CEO, Curapath: https://www.linkedin.com/in/philippe-clavel-cdmo-gxapis/ Moderated by Elliot Payne, Co-Founder and CEO, ARTO: https://www.linkedin.com/in/elliot-payne-2a4a917a/ Timestamps:0:00 Intro 0:15 Welcome to the CEO’s Weekly Challenge 0:50 How do you weigh capacity risk against indication risk? 6:50 ten23 health: the science, not the disease 9:06 Do biosimilars take indication risk out? 10:56 Curapath’s ALS customer: from 16 conjugates to four 12:28 Fixed platform, flexible indications 15:31 Fast, flexible capacity: real or a marketing ploy? 23:29 Biosimilars: flexibility or analytical rigour? 26:03 Can one facility serve many indications and be best in class? 28:29 The latest build, buy or partner call 33:35 Data or instinct? 40:34 Quickfire: one thing to remove from pharma manufacturing #MakingItInManufacturing #ARTOTalent #CPHIMilan #CPHI2026 #CDMO #PharmaManufacturing #Biotech #LifeSciences #Biosimilars #DrugDelivery Hosted on Acast. See acast.com/privacy for more information.

53Biologics is adding new lyophilisation equipment and an isolator to its facilities, completing its fill and finish capabilities so the company is fully end to end. That means the small batches first clinical trials need can stay under one roof.On Newsbeat, live at CPHI Milan 2026, Ruby Collier spoke to Javier Santos, Business Developer at 53Biologics, about the company's new in-house lyophilisation and what it means for customers' clinical programmes.In this episode, Javier covers:(00:33) 53Biologics' new lyophilisation equipment and isolator, which complete its fill and finish capabilities and make the company end to end, in line with its philosophy.(01:05) Why the small batches needed for first clinical trials are so hard to place with outside fill and finish suppliers, and how bringing the work in house removes that bottleneck, especially in phase one.(02:14) How keeping every step with one partner makes customers' projects quicker and more efficient, with no extra contracts and no separate providers' timelines to manage.(03:13) What his conversations at CPHI have confirmed: clients across many projects are asking for the same small batches, so the capability needs to be in place.Watch the full episode to hear why Javier sees having everything under one roof as the answer to the small-batch bottleneck.Register your interest for CPHI Frankfurt 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-artoFollow ARTOLinkedIn: https://www.linkedin.com/company/artotalent/Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ngInstagram: https://www.instagram.com/arto.talentTikTok: https://www.tiktok.com/@artotalentApple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575Website: https://arto-talent.com/Youtube: https://www.youtube.com/@artotalentJavier SantosLinkedIn: https://www.linkedin.com/in/javier-santos-aberturas-96b7a45a/Ruby CollierLinkedIn: https://www.linkedin.com/in/ruby-collier/Timestamps:00:00 Introduction00:52 Why small clinical batches need in-house fill and finish01:58 Simpler projects, everything in one place02:58 What CPHI conversations have confirmed03:52 Closing thoughts#Newsbeat #ARTOTalent #CPHI #CPHIMilan #FillAndFinish #Lyophilisation #Biologics #CDMO Hosted on Acast. See acast.com/privacy for more information.

95% of our viewers aren't subscribed. If you're watching and not yet subscribed, please subscribe to the channel so you don't miss future episodes. This week on Making It In Manufacturing, Thomas McMann sat down with Dr Amy Walker, CEO of 4basebio. In this episode, Amy covers: • Why DNA has been made the same way for 50 years, and what changes when you take the bacteria out of the process entirely. • How 4basebio's enzymatic platform works, and why it cuts GMP grade DNA from a 6 to 9 month wait down to under 12 weeks. • What it was actually like joining as the company's first employee, when 4basebio was an empty building on an industrial estate outside Cambridge. • The funding headwinds of the last two years, what happens when a client loses their NIH funding overnight, and how they diversified the client base around it. • Why she believes synthetic DNA disrupting plasmid is a question of when rather than if, and what she wants regulators saying about it in ten years' time. Worth watching if you work anywhere near cell and gene therapy, mRNA, viral vectors or DNA supply. Even if plasmid isn't your day to day, it's a clear look at how an established manufacturing process gets displaced, and what it takes to get conservative buyers to switch. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent/ Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent TikTok: https://www.tiktok.com/@artotalent Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/channel/UCkoSWF_xqX4i9OIkX4pGaxQ Dr Amy Walker LinkedIn: https://www.linkedin.com/in/amy-walker-4a9785154/ Thomas McMann LinkedIn: https://www.linkedin.com/in/thomas-mcmann-05540a10b Timestamps: 00:00 Introduction 01:35 What 4basebio does 02:10 Operating as a CDMO 02:48 Why plasmid DNA hasn't changed in 50 years 04:09 The safety benefits of removing bacteria 04:49 Lowering the dose required 05:23 From 6 to 9 months down to under 12 weeks 05:36 Personalised cancer vaccines 05:53 Touchlight and why there is so little competition 06:25 How mRNA vaccines changed the conversation 07:36 TruePrime and opDNA explained 08:44 Clean rooms no bigger than a podcast booth 09:46 Why cell free is the real difference 10:48 Joining 4basebio as its first employee 12:01 Head of Discovery to COO to CEO 13:09 Balancing the science and the commercial 14:14 The funding headwinds of the last two years 15:37 GMP certification and getting into the clinic 17:00 Persuading big pharma to switch 17:47 The regulatory objection 19:54 The Genezen partnership 20:32 "There was nothing to see. It was an empty building" 23:31 The advantage of having worn every hat 24:41 Where the strongest growth is coming from 26:41 The case for vertical integration 28:46 Sustainability 29:44 Where 4basebio is in ten years 30:49 Quickfire questions #MakingItInManufacturing #ARTOTalent #4basebio #SyntheticDNA #PlasmidDNA #CellAndGeneTherapy #mRNA #ViralVectors #CDMO #Biomanufacturing Hosted on Acast. See acast.com/privacy for more information.

Ensera has launched the Ensera Alliance Network at CPHI Milan 2026. It brings like-minded companies together across the value chain, from drug product manufacturing and fill finish to assembly, packaging and serialisation.On Newsbeat, live at CPHI Milan 2026, Ruby Collier spoke to Darren Hieber, VP Alliance Partnerships at Ensera, about the network and what it offers pharma companies.In this episode, Darren covers:(00:26) What the Ensera Alliance Network is: drug product CDMOs, equipment makers and platform auto-injector companies working together, with six groups in so far and plans to expand.(01:41) How the network brings well-respected specialists to a pharma company, so it no longer has to evaluate five fill finish partners and six packaging partners on its own.(02:46) Why early discussions matter, from the year of user and human factors studies after a device is chosen to a full and complete submission to the regulators.(04:03) What Ensera wants to hear from pharma companies at CPHI: referral opportunities, and the pain points the network is built to help avoid.Watch the full episode to hear how the Ensera Alliance Network plans to support patients and customer projects.Register your interest for CPHI Frankfurt 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-artoFollow ARTOLinkedIn: https://www.linkedin.com/company/artotalent/Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ngInstagram: https://www.instagram.com/arto.talentTikTok: https://www.tiktok.com/@artotalentApple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575Website: https://arto-talent.com/Youtube: https://www.youtube.com/@artotalentDarren HieberLinkedIn: https://www.linkedin.com/in/darren-hieber-59517637/Ruby CollierLinkedIn: https://www.linkedin.com/in/ruby-collier/Timestamps:00:00 Introduction01:26 How the network helps pharma02:31 Collaboration across the network03:50 What Ensera wants to hear at CPHI05:01 Closing thoughts#Newsbeat #ARTOTalent #CPHI #CPHIMilan #CombinationProducts #FillFinish #DrugDelivery #PharmaPackaging Hosted on Acast. See acast.com/privacy for more information.